120 related articles for article (PubMed ID: 16018938)
1. Relative importance of PSA in prostate cancer treatment.
Unger HA; Kane RD; Fox KM; Gandhi S; Alzola C; Lamerato L; Newling D; Kumar S
Urol Oncol; 2005; 23(4):238-45. PubMed ID: 16018938
[TBL] [Abstract][Full Text] [Related]
2. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
deVere White RW; Hackman RM; Soares SE; Beckett LA; Li Y; Sun B
Urology; 2004 Feb; 63(2):259-63. PubMed ID: 14972467
[TBL] [Abstract][Full Text] [Related]
3. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
4. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
5. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
6. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
Zhou P; Chen MH; McLeod D; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Oct; 23(28):6992-8. PubMed ID: 16192586
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
8. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
Carter CA; Donahue T; Sun L; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Jackmaan S; Moul JW
J Clin Oncol; 2003 Nov; 21(21):4001-8. PubMed ID: 14581423
[TBL] [Abstract][Full Text] [Related]
9. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation.
Ludgate CM; Bishop DC; Pai H; Eldridge B; Lim J; Berthelet E; Blood P; Piercy GB; Steinhoff G
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1309-15. PubMed ID: 16029786
[TBL] [Abstract][Full Text] [Related]
11. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
[TBL] [Abstract][Full Text] [Related]
12. Initial treatment patterns for clinically localized prostate cancer and factors associated with the treatment in Louisiana.
Wu X; Chen VW; Andrews PA; Chen L; Ahmed MN; Schmidit B; Hsieh M; Fontham ET
J La State Med Soc; 2005; 157(4):188-94. PubMed ID: 16250368
[TBL] [Abstract][Full Text] [Related]
13. Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center.
Koff SG; Connelly RR; Bauer JJ; McLeod DG; Moul JW
Prostate Cancer Prostatic Dis; 2002; 5(2):152-8. PubMed ID: 12497006
[TBL] [Abstract][Full Text] [Related]
14. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
15. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
16. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
[TBL] [Abstract][Full Text] [Related]
17. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.
Ross RW; Manola J; Hennessy K; Galsky M; Scher H; Small E; Kelly WK; Kantoff PW
Clin Cancer Res; 2005 Jul; 11(14):5195-8. PubMed ID: 16033836
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
[TBL] [Abstract][Full Text] [Related]
20. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
